2-n-butyl-5-substituted aminobenzofuran and its preparation method
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- AVENTIS PHARMA HAINAN
- Publication Date
- 2016-05-04
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The present invention relates to a key intermediate of dronedarone represented by formula I and a preparation method thereof.
[0002] Background technique
[0003] Dronedarone (dronedarone), the chemical name is N-[2-n-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-5-benzofuryl] Methylsulfonamide, developed by Sanofi-Aventis of France, can be used to treat atrial fibrillation / flutter. In July 2009, it was approved for marketing by the US Food and Drug Administration (FDA).
[0004]
[0005] dronedarone
[0006] Atrial fibrillation is a complex disease that can increase the risk of stroke by 5 times, worsen the prognosis and triple the mortality rate of patients with cardiovascular risk factors. Atrial flutter is another type of atrial arrhythmia that occurs less frequently but may develop into atrial fibrillation. In the United States, atrial fibrillation is the leading cause of hospitalizations for arrhythmias, and the number of hospitalizati...